Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.

Qiu Y, Li Z, Copland JA, Mehrling T, Tun HW.

Oncotarget. 2018 Jun 15;9(46):28155-28164. doi: 10.18632/oncotarget.25588. eCollection 2018 Jun 15.

2.

Observation of the Self-Modulation Instability via Time-Resolved Measurements.

Gross M, Engel J, Good J, Huck H, Isaev I, Koss G, Krasilnikov M, Lishilin O, Loisch G, Renier Y, Rublack T, Stephan F, Brinkmann R, Martinez de la Ossa A, Osterhoff J, Malyutin D, Richter D, Mehrling T, Khojoyan M, Schroeder CB, Grüner F.

Phys Rev Lett. 2018 Apr 6;120(14):144802. doi: 10.1103/PhysRevLett.120.144802.

3.

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

Festuccia C, Mancini A, Colapietro A, Gravina GL, Vitale F, Marampon F, Delle Monache S, Pompili S, Cristiano L, Vetuschi A, Tombolini V, Chen Y, Mehrling T.

J Hematol Oncol. 2018 Mar 14;11(1):38. doi: 10.1186/s13045-018-0587-3.

4.

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

Festuccia C, Mancini A, Colapietro A, Gravina GL, Vitale F, Marampon F, Delle Monache S, Pompili S, Cristiano L, Vetuschi A, Tombolini V, Chen Y, Mehrling T.

J Hematol Oncol. 2018 Feb 27;11(1):32. doi: 10.1186/s13045-018-0576-6. Erratum in: J Hematol Oncol. 2018 Mar 14;11(1):38.

5.

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.

Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C.

Blood Cancer J. 2017 Jul 28;7(7):e589. doi: 10.1038/bcj.2017.69. No abstract available.

6.

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

López-Iglesias AA, Herrero AB, Chesi M, San-Segundo L, González-Méndez L, Hernández-García S, Misiewicz-Krzeminska I, Quwaider D, Martín-Sánchez M, Primo D, Paíno T, Bergsagel PL, Mehrling T, González-Díaz M, San-Miguel JF, Mateos MV, Gutiérrez NC, Garayoa M, Ocio EM.

J Hematol Oncol. 2017 Jun 20;10(1):127. doi: 10.1186/s13045-017-0495-y.

7.

Chirp Mitigation of Plasma-Accelerated Beams by a Modulated Plasma Density.

Brinkmann R, Delbos N, Dornmair I, Kirchen M, Assmann R, Behrens C, Floettmann K, Grebenyuk J, Gross M, Jalas S, Mehrling T, Martinez de la Ossa A, Osterhoff J, Schmidt B, Wacker V, Maier AR.

Phys Rev Lett. 2017 May 26;118(21):214801. doi: 10.1103/PhysRevLett.118.214801. Epub 2017 May 23.

8.

Mitigation of the Hose Instability in Plasma-Wakefield Accelerators.

Mehrling TJ, Fonseca RA, Martinez de la Ossa A, Vieira J.

Phys Rev Lett. 2017 Apr 28;118(17):174801. doi: 10.1103/PhysRevLett.118.174801. Epub 2017 Apr 26.

9.

Is there hope to treat glioblastoma effectively?

Mehrling T, Gunawardana R.

CNS Oncol. 2015;4(6):377-9. doi: 10.2217/cns.15.33. Epub 2015 Oct 28.

10.
11.

Chemotherapy is getting 'smarter'.

Mehrling T.

Future Oncol. 2015;11(4):549-52. doi: 10.2217/fon.14.248. No abstract available.

PMID:
25686110
12.

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.

Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.

Haematologica. 2014 Jul;99(7):1228-35. doi: 10.3324/haematol.2013.101741. Epub 2014 Apr 11.

13.

High-quality electron beams from beam-driven plasma accelerators by wakefield-induced ionization injection.

Martinez de la Ossa A, Grebenyuk J, Mehrling T, Schaper L, Osterhoff J.

Phys Rev Lett. 2013 Dec 13;111(24):245003. Epub 2013 Dec 10.

14.

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

Alonso R, López-Guerra M, Upshaw R, Bantia S, Smal C, Bontemps F, Manz C, Mehrling T, Villamor N, Campo E, Montserrat E, Colomer D.

Blood. 2009 Aug 20;114(8):1563-75. doi: 10.1182/blood-2009-02-207654. Epub 2009 Jun 18.

Supplemental Content

Loading ...
Support Center